Pharmacogenomics: The Key to Improved Drug Therapy in Transplant Patients

Clinics in Laboratory Medicine

Volumn 28, Issue 3, 2008, Pages 411-422

  Burckart, Gilbert J ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BIOLOGICAL MARKER; CALCINEURIN INHIBITOR; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN; CYTOCHROME P450 3A5; GLYCOPROTEIN P; GLYCOSYLTRANSFERASE; IMMUNOSUPPRESSIVE AGENT; INOSINATE DEHYDROGENASE; IRINOTECAN; MERCAPTOPURINE; METHYLPREDNISOLONE; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; RAPAMYCIN; TACROLIMUS; THIOPURINE METHYLTRANSFERASE; UNCLASSIFIED DRUG; URIDINE GLYCOSYLTRANSFERASE; WARFARIN;

DIABETES MELLITUS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG DISPOSITION; DRUG LIVER LEVEL; DRUG METABOLISM; DRUG RESPONSE; GENETIC POLYMORPHISM; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; NEPHROTOXICITY; ORGAN TRANSPLANTATION; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

BIOMARKERS, PHARMACOLOGICAL; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MODELS, IMMUNOLOGICAL; MONITORING, IMMUNOLOGIC; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PROTEINS; TREATMENT OUTCOME;

EID: 56349130877     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cll.2008.09.004     Document Type: Review

References (33)

1. Burckart G.J., Amur S., Goodsaid F.M., et al. Qualification of biomarkers for drug development in organ transplantation. Am J Transplant 8 (2008) 267-270
2. Zheng H., Webber S., Schuetz E., et al. Cytochrome P4503A and TNF-α genotypes are associated with tacrolimus dosing in pediatric heart transplant patients. Hum Immunol 63 Suppl 1 (2002) S15
3. Wojnowski L. Genetics of the variable expression of CYP3A in humans. Ther Drug Monit 26 (2004) 192-199
4. Girnita D.M., Webber S.A., Ferrell R., et al. Disparate distribution of 16 candidate single nucleotide polymorphisms among racial and ethnic groups of pediatric heart transplant patients. Transplantation 82 (2006) 1774-1780
5. Anglicheau D., Thervet E., Etienne I., et al. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Pharmacol Ther 75 (2004) 422-433
6. Zheng H., Zeevi A., Schuetz E., et al. Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism. J Clin Pharmacol 44 (2004) 135-140
7. Yu S., Wu L., Jin J., et al. Influence of CYP3A5 gene polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation. Transplantation 81 (2006) 46-51
8. Wei-lin W., Jing J., Shu-sen Z., et al. Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients. Liver Transpl 12 (2006) 775-780
9. Haufroid V., Wallemacq P., VanKerckhove V., et al. CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study. Am J Transplant 6 (2006) 2706-2713
10. Op den Buijsch R.A., Christiaans M.H., Stolk L.M., et al. Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms. Fundam Clin Pharmacol 21 (2007) 427-435
11. Ng F.L., Holt D.W., and MacPhee I.A. Pharmacogenetics as a tool for optimising drug therapy in solid organ transplantation. Expert Opin Pharmacother 8 (2007) 2045-2058
12. Kuypers D.R., de Jonge H., Naesens M., et al. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther 82 (2007) 711-725
13. Anglicheau D., Legendre C., and Thervet E. Pharmacogenetics of tacrolimus and sirolimus in renal transplant patients: from retrospective analyses to prospective studies. Transplant Proc 39 (2007) 2142-2144
14. Le Meur Y., Djebli N., Szelag J.C., et al. CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. Clin Pharmacol Ther 80 (2006) 51-60
15. Lee S.J., Jusko W.J., Salaita C.G., et al. Reduced methylprednisolone clearance causing prolonged pharmacodynamics in a healthy subject was not associated with CYP3A5*3 allele or a change in diet composition. J Clin Pharmacol 46 (2006) 515-526
16. Ferraresso M., Tirelli A., Ghio L., et al. Influence of the CYP3A5 genotype on tacrolimus pharmacokinetics and pharmacodynamics in young kidney transplant recipients [see comment]. Pediatr Transplant 11 (2007) 296-300
17. Zheng H., Webber S., Zeevi A., et al. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant 3 (2003) 477-483
18. Elens L., Capron A., Kerckhove V.V., et al. 1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation. Pharmacogenet Genomics 17 (2007) 873-883
19. Fanta S., Niemi M., Jonsson S., et al. Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms. Pharmacogenet Genomics 18 (2008) 77-90
20. Hauser I.A., Schaeffeler E., Gauer S., et al. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol 16 (2005) 1501-1511
21. Zheng H., Webber S., Zeevi A., et al. The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant patients. Hum Immunol 63 (2002) 765-770
22. Zheng H.X., Webber S.A., Zeevi A., et al. The impact of pharmacogenomic factors on steroid dependency in pediatric heart transplant patients using logistic regression analysis. Pediatr Transplant 8 (2004) 551-557
23. Wang J., Figurski M., Shaw L.M., et al. The impact of P-glycoprotein and Mrp2 on mycophenolic acid levels in mice. Transpl Immunol 19 (2008) 192-196
24. Naesens M., Kuypers D.R., Verbeke K., et al. Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation 82 (2006) 1074-1084
25. Ohmann E.L., Burckart G.J., Chen Y., et al. Impact of inosine 5′-monophosphate dehyrogenase 1,2 and multidrug resistance protein 2 genetic polymorphisms on mycophenolate mofetil-related adverse events in pediatric heart transplant patients. J Heart Lung Transplant 27 (2008) S181
26. Miura M., Satoh S., Inoue K., et al. Influence of SLCO1B1, 1B3, 2B1, and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol 63 (2007) 1161-1169
27. Sahasranaman S., Howard D., Roy S., et al. Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol 64 (2008) 753-767
28. Thervet E., Anglicheau D., Legendre C., et al. Role of pharmacogenetics of immunosuppressive drugs in organ transplantation. Ther Drug Monit 30 (2008) 143-150
29. Cattaneo D., Baldelli S., and Perico N. Pharmacogenetics of immunosuppressants: progress, pitfalls, and promises. Am J Transplant 8 (2008) 1374-1383
30. Wang J., Zeevi A., Webber S., et al. A novel variant L263F in human inosine 5′-monophosphate dehydrogenase 2 is associated with diminished enzyme activity. Pharmacogenet Genomics 17 (2007) 283-290
31. Wang J., Yang J.W., Zeevi A., et al. IMPDH1 gene polymorphisms and association with acute rejection in renal transplant patients. Clin Pharmacol Ther 83 (2008) 711-717
32. Burckart G.J., Frueh F.W., and Lesko L.J. Progress in the direct application of pharmacogenomics to patient care: sustaining innovation. J Appl Pharmacol 15 (2007) 1-6
33. Dosage calculation algorithm. Available at: http://www.warfarindosing.org. Barnes-Jewish Hospital at Washington University Medical Center. Accessed November 2, 2008.